Pennsylvania is currently home to 3447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Philadelphia, Pennsylvania
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Register for Updates
Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
NCT05705986
Recruiting
Microparticles (MPs) as a mode of therapeutic delivery can selectively deliver immunomodulatory treatment to the phagocytic cells, particularly dendritic cells (DCs), inducing their tolerogenic phenotype and function and T regulatory (Treg) cell expansion. The study will characterize the in vitro response of cGAMP immunomodulator incapsulated microparticles on the capacity of DCs and Tregs to regulate the inflammatory response.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/20/2023
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Relapse Remitting Multiple Sclerosis
Register for Updates
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Gettysburg Cancer Center, Gettysburg, Pennsylvania
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Rett Syndrome Registry
NCT05432349
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
All
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Register for Updates
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: University of Pennsylvania - Roberts Proton Therapy Center, Philadelphia, Pennsylvania
Conditions: Pediatric Patients Treated With Radiation Therapy
Register for Updates
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
NCT05314764
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
NCT05137314
Recruiting
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2022
Locations: Rothman, Philadelphia, Pennsylvania
Conditions: Joint Infection
Register for Updates
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT04931823
Recruiting
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/16/2022
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor
Register for Updates
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728
Recruiting
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/06/2022
Locations: Frontier Clinical Research, LLC, Smithfield, Pennsylvania
Conditions: COVID-19
Register for Updates
Knee Related Subchondral Bone Lesions Treated With IOBP
NCT05314608
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania
Conditions: Subchondral Cyst
Register for Updates
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
NCT03583164
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: UPMC, Pittsburgh, Pennsylvania
Conditions: Invasive Fungal Infections
Register for Updates